NDAORALSUSPENSION
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
2/8 — Basic
Drug data last refreshed 11h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALLEGRA (fexofenadine HCl) is a second-generation selective H1-receptor antagonist oral suspension approved for allergic rhinitis and chronic urticaria. It is a non-sedating antihistamine that provides rapid symptom relief without CNS penetration. The drug works by competitively blocking histamine at peripheral H1 receptors to reduce allergic responses.
LOE Approaching
As LOE approaches, brand team size is likely optimizing and may shift focus to lifecycle extension strategies, digital engagement, and cost containment; limited growth opportunities remain for new hires.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
Started Jun 2025
203 enrolled
Rhinitis Allergic
All Women Comparing Self-expanding ALLEGRA Valve to Any Other Balloon-expandable Valve
Started Feb 2024
130 enrolled
Aortic Stenosis, Severe
Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis
Started Feb 2011
520 enrolled
Rhinitis Seasonal
Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition
Started Feb 2011
80 enrolled
Healthy
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)
Started Nov 2010
100 enrolled
Atopic Dermatitis
Worked on ALLEGRA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.